Abstract
BackgroundMethotrexate (MTX) is the DMARD of first choice in most patients with rheumatoid arthritis (RA). However, a significant minority (30-40%) of patients do not respond to MTX therapy. Gene expression...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have